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Abstract 
Background 
Chloride plays a role in renal salt sensing, neurohormonal activation and regulation of 
diuretic targets, and hypochloremia predicts mortality in acute heart failure (AHF).  AHF 
therapies such as diuretics alter chloride homeostasis. We studied the association between 
(changes in) chloride levels and diuretic responsiveness, decongestion, and mortality in 
patients with AHF.  
Methods and results 
Patients hospitalized for AHF in the PROTECT trial (n=2033) with serum chloride levels within 
24 hours of admission and 14 days later were studied. Hypochloremia was defined as 
chloride < 96 mEq/L.  
Median baseline chloride was 101.0 [97.0-104.0] mEq/L. Low baseline chloride was 
associated with high bicarbonate, poor diuretic response, less hemoconcentration, and 
more worsening heart failure (all P<0.01). Newly developed hypochloremia at day 14 was 
common and associated with a decline in renal function, and increase in blood urea nitrogen 
(P<0.01). Baseline chloride was not significantly associated with mortality after multivariable 
adjustment, however day 14 chloride was strongly and independently associated with 180-
day mortality (HR per SD decrease: 1.33 [1.17-1.50], P<0.001). Hypochloremia at baseline 
that resolved was not associated with mortality (p=0.55), but new or persistent 
hypochloremia at day 14 was associated with increased mortality (HR: 3.11 [2.17-4.46, 
P<0.001].  
Conclusions 
Hypochloremia at AHF hospital admission was strongly associated with impaired 
decongestion.  New or persistent hypochloremia 14 days later was independently associated 
with reduced survival, whereas hypochloremia that resolved by day 14 was not.   
Abbreviations 
BUN  Blood Urea Nitrogen 
eGFR  Estimated Glomerular Filtration Rate 
PROTECT Placebo-controlled Randomized Study of the Selective A1 antagonist 
Rolofylline for Patients Hospitalized with Acute Decompensated Heart 
Failure and Volume Overload to Assess Treatment Effect on Congestion and 
Renal Function 
 
  
Introduction 
During hospitalization for acute heart failure, renal function and electrolytes are 
usually closely monitored, as diuretics are known to affect both. Guidelines recommend 
daily monitoring of blood urea nitrogen (BUN), creatinine, potassium, and sodium during 
intravenous diuretic therapy. 1-3  Interestingly, chloride is not mentioned in this list and 
similarly research studies investigating the role of chloride are scarce, even though chloride, 
and not sodium, has a predominant role in renal salt sensing mechanisms. 4,5  Also, tubular 
glomerular feedback and renin release have been shown to be primarily driven by chloride 
rather than sodium. 6  Chloride is a critical regulator of sodium transporter pathways through 
phosphorylation of a family of serine-threonine kinases. 7,8   
Recently, two studies demonstrated a strong, independent association between 
hypochloremia and an increased risk of mortality in both acute and chronic heart failure. 9,10  
Both of these studies demonstrated that the prognostic value of chloride was greater than 
that of sodium. Given the influence of chloride on the targets of diuretic therapy, we sought 
to determine if hypochloremia is associated with reduced diuretic response and 
decongestion. Reciprocally given the effect of diuretics on chloride homeostasis, we 
furthermore aimed to evaluate changes in serum chloride and the prognostic significance of 
these changes.  
 
 
Methods 
Study design and procedures 
The study population and design of the Placebo-controlled Randomized Study of the 
Selective A1 antagonist Rolofylline for Patients Hospitalized with Acute Decompensated 
Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal 
Function (PROTECT) study has been described in detail previously. 11  The PROTECT study 
was a large, multicenter, phase III randomized clinical trial, that enrolled 2,033 patients 
hospitalized for acute heart failure with mild to moderate renal dysfunction. The local ethics 
committed at each participating center approved the trial, and all patients provided written 
informed consent. The primary endpoint of treatment success, failure, or no change was 
neutral, and no effect was seen on 180-day mortality. 
At baseline signs and symptoms of heart failure were assessed. Standard laboratory 
assessments were performed at baseline, day 7, and day 14. Diuretic response was defined 
as weight change on day 4 per 40 mg of intravenous furosemide (or equivalent doses) 
administered from baseline to day 3. 12  Estimated glomerular filtration rate (eGFR) was 
calculated using the Cockcroft-Gault equation. Hemoconcentration was defined as an 
increase in hemoglobin from baseline to day 4. Worsening renal function was defined as an 
increase ≥ 0.3 mg/dL from baseline to day 7 or 14, and a percentage change > 25%. The 
endpoint selected for this analysis was 180-day mortality. 
 
Chloride  
Chloride at baseline was available in 1960 patients (96%), at day 7 in 1814 patients (89%), 
and at day 14 in 1783 patients (88%). Hypochloremia was defined as a serum chloride 
concentration ≤ 96 mmol/L. 13 Chloride was missing due to death at 7 and 14 days in 86 
patients (4%). Performing the primary analyses in the subgroup of patients without missing 
chloride data (n=1649) yielded similar results (data not shown). 
 
Statistical analysis 
The analyses were performed in the intention to treat population. Continuous variables are 
presented as mean ± standard deviation or median with [interquartile range] when 
appropriate. Categorical values are presented as frequencies and percentages. A linear trend 
was statistically tested over quintiles of diuretic response, after checking for non-linear 
trends. Correlation coefficients presented are Spearman’s. Uni- and multivariable linear 
regression analysis was performed with transformed values when necessary. 
Transformations were checked using multifractional polynomials. Multivariable explanatory 
regression models, including all univariable variables with a p-value < 0.10, were constructed 
via backward elimination. Cox proportional hazard regression analysis and Kaplan Meier 
survival estimates were performed to investigate the association of chloride with the 
selected endpoints. Multivariable models were corrected for study treatment and clinical 
covariates from a previously published model developed in PROTECT. 14  The added value of 
chloride for estimating the risk of mortality was assessed by examining gain in Harrell’s C-
index (a measure of model discrimination, higher values are better), using likelihood ratio 
tests for nested survival models, and assessment of continuous net reclassification 
improvement (NRI, a category-independent measure quantifying the degree of 
improvement in model-based risk estimates obtained by adding a marker to a model). A P-
value <0.1 for interactions, and a two tailed P value < 0.05 was considered statistically 
significant. Analyses were performed using R: a Language and Environment for Statistical 
Computing, version 3.0.2. (R Foundation for Statistical Computing, Vienna, Austria). 
 
 
Results 
Baseline chloride and clinical characteristics 
Median admission chloride was 101.0 [97.0-104.0] mEq/L and baseline characteristics per 
quintile of chloride are presented in table 1. Lower chloride levels were associated with 
younger age, lower ejection fraction and lower systolic and diastolic blood pressure (all 
P<0.03). In addition, lower chloride was associated with lower sodium, higher BUN, higher 
bicarbonate, and higher hemoglobin (P<0.001). Interestingly, eGFR, creatinine, and (NT-pro) 
BNP were not different over quintiles of chloride.  
 
Response to decongestive therapy: 
Across quintiles of chloride, a lower chloride was associated with poorer diuretic response 
(kg weight loss per 40mg furosemide, Table 2). Furthermore, there was less weight change, 
higher diuretic doses, and more frequent requirement for adjuvant thiazide diuretics or 
inotropes during hospitalization in patients with hypochloremia (table 2, all P<0.01). In 
addition, low chloride was strongly associated to a lower rate of improvement in 
intravascular volume as indicated by a 20% absolute difference in the rate of 
hemoconcentration across quintiles of chloride (Table 2). Chloride remained significantly 
associated with diuretic response, even after correction for sodium and bicarbonate levels in 
addition to potential baseline and in hospital confounders (p<0.001).  There was no 
significant difference in the incidence of worsening renal function over quintiles of chloride. 
Odds ratios for markers of poor decongestion and hypochloremia are shown in figure 1. 
 
Chloride levels and outcome 
In univariable Cox regression analysis, lower baseline chloride was associated with a higher 
risk of 180-day mortality (HR per SD decrease: 1.35 [1.22-1.49], P<0.001), however, after 
adjusting for baseline sodium, baseline chloride was no longer predictive of mortality 
(P=0.163) whereas sodium remained significantly associated (P<0.001). Notably, upon 
multivariable adjustment for baseline characteristics, neither baseline sodium nor chloride 
remained associated with outcome (Table 3). Addition of baseline chloride to a multivariable 
model containing sodium resulted in no improvement in model performance (P=0.627, 
Supplementary table 1).  
Lower chloride levels at day 7 and day 14 were associated with a higher risk of 180-day 
mortality in both univariable and multivariable models, whereas day 7 and day 14 sodium 
levels were not predictive (table 3). Figure 2 shows the adjusted hazard ratios for sodium 
and chloride at different time points.  
Addition of day 7 or 14 chloride to a multivariable model that included sodium at the same 
time point, significantly, though modestly improved the c-statistic (from 0.72 to 0.73; 
P<0.001, for both day 7 and day 14 chloride), and NRI (P<0.01, supplementary table 1). 
There was no significant interaction between sodium and chloride at any time point. A 
significant interaction between day 14 chloride and day 14 bicarbonate was observed where 
the risk associated with lower chloride was greater in patients with higher levels of 
bicarbonate. However this did not reduce the predictive value of day 14 chloride on 180-day 
mortality (supplementary table 2).  
 
Change in chloride levels 
On average, chloride levels in the overall population were stable over time (supplementary 
figure 1), and median chloride at baseline day 7 and day 14 were respectively 101.0 [97.0-
104.0] mEq/L, 100 [96.0-103.0] mEq/L, and 101.0 [97.0-104.0] mEq/L. However, there were 
important individual changes in chloride levels, which explains the modest correlations 
between baseline and day 7 or day 14 chloride levels (r=0.60, P<0.001 and r=0.57, P<0.001). 
Comparing patients with hypochloremia at baseline and 14 days (Table 4) we find that 45% 
of patients with hypochloremia at day 1 no longer had hypochloremia by 14 days, and 59% 
of hypochloremia at day 14 was newly developed (figure 3). The majority of baseline and 
treatment related parameters were remarkably similar between patients whose 
hypochloremia was stable, improved, or worsened (table 4). The most notable difference we 
found in terms of clinical characteristics between these groups was a significant increase in 
BUN from day 1 to day 14, and a decrease in eGFR in patients with who developed new 
hypochloremia at day 14 (table 4). There was no significant difference in changes in sodium 
or bicarbonate. Additionally, rolofylline administration was not associated with changes in 
chloride levels (P=0.782).    
 
Change in chloride and outcomes: 
A decrease in chloride from baseline to either day 7 or day 14 were both associated with an 
increased risk of 180-day mortality irrespective of baseline sodium and baseline chloride 
levels (supplementary table 3). However, the change seemed to be less important than the 
ultimate level of chloride achieved since after adjustment for day 14 chloride levels the 
change was no longer significant (supplementary Table 3). Patients with hypochloremia at 
baseline that persisted to day 14, and patients that newly developed hypochloremia by day 
14 had 2-3 fold increase in the rate of mortality compared to patients without 
hypochloremia (HR: 3.11 [2.17-4.46], P<0.001, compared to patients with no hypochloremia 
at day 1 and day 14). Remarkably, as shown in table 4 the risk of 180-day mortality for 
patients with baseline hypochloremia whose chloride returned to normal by day 14 was 
comparable to patients who never had hypochloremia (HR: 1.19 [0.67-2.09], P=0.550, 
compared to patients with no hypochloremia at day 1 and day 14). Sensitivity analyses did 
not identify baseline or treatment related factors that could explain which patients with 
hypochloremia at day 14 were at higher risk for adverse outcomes (data not shown) or the 
reasons for improvement or worsening in serum chloride with treatment.  Notably, a 
multivariable linear regression analysis (including all variables in table 1, and decongestion 
parameters from table 2) explained only 11% of the variance in change in chloride from 
baseline to day 14 (supplementary table 4).   
 
 
Discussion 
The principle findings of this study are that a low serum chloride is associated with a 
lower diuretic response, less decongestion, and increased mortality. We found that 
significant changes in serum chloride were very common during the treatment of AHF with 
approximately half of hypochloremic patients either resolving or developing new 
hypochloremia. Importantly, baseline hypochloremia that normalized during admission was 
not associated with adverse outcomes, whereas new or persistent hypochloremia was 
associated with 2-3 fold increased risk of mortality. Given the important role for chloride in 
neurohormonal and sodium homeostatic pathways, these associations might suggest that 
modulation of serum chloride may possibly improve diuretic response and potentially 
outcomes in patients with acute heart failure.  
  
Chloride and response to therapy 
Chloride has a great number of functions in the body, and deregulation of chloride 
results in a wide range of abnormalities. 15,16  Chloride has an important role in salt sensing, 
and seems to be the main driver in the kidneys ability to sense volume overload, as chloride 
containing solutions, but not non-chloride containing sodium solutions, elicited a response 
from the kidney. 4,5  Chloride has also been shown to reduce renin release, in contrast to 
non-chloride containing sodium salts which do not affect renin levels. 6  The role of chloride 
in regulation and response to volume retention in acute heart failure, is therefore of great 
interest as both fluid regulation and renin-angiotensin-aldosterone activation are 
deregulated in this setting.  
Recent evidence suggests an association between chloride and diuretic targets. 
Several studies showed that sensing of hypochloride by WNKs (with no lysine K) causes 
upregulation of the sodium-potassium-chloride cotransporter (NKKC2). 7,8  Binding of 
chloride to the active site of WNK inhibits autophosphorylation and therefore decreases the 
availability of both NKCC2 and NCC and consequently reduces renal salt reabsorption. Both 
the activity of loop diuretics, the most common therapy in acute heart failure that is 
prescribed to over 90% of all acute heart failure patients, and thiazide diuretics appear to be 
regulated by chloride.  
In this study, we found a consistent association between lower baseline chloride 
levels and poor decongestion. We assessed multiple markers of decongestion, such as 
diuretic response, hemoconcentration, and physician assessed worsening heart failure, and 
found large difference of these parameters across the quintiles of chloride. We especially 
observed a remarkable difference in hemoconcentration, which was 20% more prevalent in 
the highest chloride quintile, compared to the lowest quintile. However, this study is 
observational and does not allow to assume a causative relationship. It may nonetheless be 
speculated that repletion of chloride might decrease fluid overload and subsequently 
improve decongestion, as evidence suggest a direct effect of chloride on reducing salt 
reabsorption through regulation of sodium transporters. In this scenario chloride itself 
would be one of the drivers of fluid overload and poor response to therapies. On the other 
hand chloride depletion could also be a result of therapy and hence be a sign of a more 
severe heart failure patient. Either mechanistic studies, or interventional chloride studies 
may be warranted to distinguish between these two possible scenarios.  
 
Chloride levels over time and association with outcome 
Despite overall stable levels of chloride over time in our entire study population, we 
observed great individual variation in chloride levels at different time points, and modest 
correlations between chloride levels at different time points. The shift in and out of 
hypochloremia might be a consequence of treatment, as loop diuretics block the NKCC2 in 
the kidney and generally cause a disproportionate excretion of chloride compared to 
sodium. 17  As such it is likely that hypochloremia at day 7, and day 14 may at least in part be 
diuretic treatment induced. In this study we found a greater predictive value of outcome for 
day 7 and day 14 chloride, compared to baseline chloride. Interestingly, baseline 
hypochloremia was free from adverse prognostic significance as long as it resolved with 
treatment, whereas new or persistent hypochloremia was associated with 2-3 fold increase 
risk of mortality. The possibility that treatment induced changes in chloride are important is 
further supported by our finding that patients with higher levels of bicarbonate, which is 
retained by the body in response to chloride wasting, 18  have a higher risk of adverse 
outcome for any given decrease in chloride, compared to patients with normal bicarbonate 
levels. The increased impaired outcome associated with new-onset or persistent 
hypochloremia, compared to resolved baseline hypochloremia suggests that chloride is not 
just a marker of risk, as this would generate a greater risk associated with baseline 
hypochloremia, even when it resolved. Conversely our results show that new onset or 
persistent hypocholoremia carries greater prognostic significance.  
Finally, we also found that a decrease in chloride levels over time was independently 
predictive of adverse outcome. Significance of the change in chloride was however lost after 
correction for the chloride level achieved at day 7 or day 14, indicating that the final value of 
chloride achieved contains more prognostic information than the change itself. A 
multivariable regression analysis for the change in chloride did not find important factors 
that could explain this change. More speculative, another explanation could be that the 
resultant chloride after a massive challenge to chloride homeostasis from treatment for 
acute heart failure is what makes the difference, rather than the change itself. Additional 
validation of our findings is required, however based on these results prospective studies 
investigating either chloride sparing therapies, or chloride replacement may be considered.    
 
Limitations 
This study is a post hoc analysis of a randomized controlled trial with all limitations 
as such. Additionally, we did not have long-term follow-up chloride data available and were 
not able to study whether restoration of chloride levels attenuated the increased risk of 
adverse outcome over time.  
  
  
Conclusion 
Low baseline chloride was strongly associated with markers of poor decongestion. 
Hypochloremia after hospitalization for AHF, but not at baseline was strongly associated 
with mortality, suggesting the resultant chloride level carries greatest prognostic 
importance. 
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Figure legends 
Figure 1: Odds ratios for hypochloremia and markers of poor decongestion 
 
 
 
  
Figure 2: Adjusted hazard ratios 180-day mortality for different time points of sodium and 
chloride 
 
  
Figure 3: Percentages of hypochloremia on day 1 or day 14, or both 
   
Table 1: Clinical characteristics per quintile of baseline chloride 
 
 Q1 Q2 Q3 Q4 Q5 P for 
trend 
N = 431 430 346 452 301   
Chloride (mEq/L) 95.0 
[92.0-
96.0] 
99.0 [98.0-
100.0] 
101.0 
[101.0-
102.0] 
104.0 
[103.0-
105.0] 
107.0 
[106.0-
109.0] 
 
Demographics       
Sex (% Male (n)) 64.5 (278) 68.1 (293) 68.5 (237) 65.9 (298) 67.1 (202) 0.683 
Age (years) 68.8±12.3 70.4±11.9 69.5±12.2 71.1±10.9 71±10.2 0.009 
LVEF (%) 31.3±14.4 31±12.9 32.9±12.5 32.8±11.9 33.8±12.5 0.025 
Systolic Blood Pressure 
(mmHg) 
117.5±17.
4 
121.8±16.
9 
125.9±16.8 128±17.3 130.7±16.5 <0.00
1 
Diastolic Blood 
Pressure (mmHg) 
70.2±12.4 73±11.2 74.8±11.2 75.3±11.5 77.1±11.6 <0.00
1 
Heart Rate (beats/min) 79.6±16.5 80±15.5 79.5±13.5 81.6±15.9 80±15.1 0.330 
Rolofylline 
administration (%(n)) 
64 (276) 69.5 (299) 64.7 (224) 69.9 (316) 65.1 (196) 0.576 
Medical History       
Hypertension (%(n)) 71.2 (307) 77.4 (333) 80.1 (277) 82.1 (371) 88.4 (266) <0.00
1 
PCI (%(n)) 26.9 (115) 30.5 (130) 27.6 (94) 22.5 (101) 21.4 (64) 0.009 
CABG (%(n)) 27.6 (118) 23.5 (100) 20.9 (71) 17.7 (80) 15.7 (47) <0.00
1 
NYHA Class (%(n))      <0.00
1 
I-II 16.7 (72) 16.7 (72) 15.9 (55) 19.2 (87) 15.6 (47)  
III 49.4 (213) 48.4 (208) 52.3 (181) 45.4 (205) 46.2 (139)  
IV 28.5 (123) 28.1 (121) 25.7 (89) 31.2 (141) 35.2 (106)  
ICD therapy (%(n)) 24.4 (105) 18.6 (80) 15.3 (53) 10 (45) 9.3 (28) <0.00
1 
Prior Medication Use       
ACE inhibitors or ARB 
(%(n)) 
71.5 (308) 77 (331) 76.6 (265) 78.9 (356) 73.8 (222) 0.200 
Beta blockers (%(n)) 79.4 (342) 79.5 (342) 73.7 (255) 74.5 (336) 75.1 (226) 0.035 
Mineralocorticoid 
Receptor Antagonists  
(%(n)) 
49.2 (212) 46.3 (199) 42.2 (146) 42.1 (190) 39.9 (120) 0.004 
Calcium Antagonists 
(%(n)) 
8.8 (38) 12.3 (53) 13.6 (47) 15.1 (68) 19 (57) <0.00
1 
Laboratory Values       
Creatinine (mg/dL) 1.4 [1.2-
1.8] 
1.4 [1.1-
1.7] 
1.4 [1.1-
1.7] 
1.4 [1.1-
1.7] 
1.4 [1.1-
1.9] 
0.329 
eGFR (ml/min/1.73m2) 47.2 
[36.3-
61.4] 
49.1 [37.9-
63] 
50.8 [37.3-
64.9] 
49.4 [37.3-
64.2] 
47.9 [35.6-
65.3] 
0.326 
Blood Urea Nitrogen 
(mg/dL) 
33 [24-48] 30 [22-40] 28 [21-38] 28 [22-39] 28 [22-39] <0.00
1 
Sodium (mmol/L) 135 [133-
138] 
138 [136-
141] 
140 [138-
142] 
141 [140-
143] 
143 [141-
145] 
<0.00
1 
Potassium (mmol/L) 4.2 [3.8- 4.2 [3.8- 4.2 [3.9- 4.2 [3.9- 4.4 [4-4.8] <0.00
4.6] 4.6] 4.6] 4.6] 1 
Bicarbonate (mEq/L) 25 [22-28] 24 [22-27] 24 [22-26] 23 [21-26] 22 [20-25] <0.00
1 
Hemoglobin (g/dL) 12.8±2.1 12.8±2 12.8±1.9 12.7±1.8 12.2±2 <0.00
1 
NT-proBNP (pg/mL) 3000 
[3000-
4726] 
3000 
[3000-
3294] 
3000 
[3000-
3947.8] 
3000 
[3000-
3847.8] 
3000 
[3000-
3153] 
0.330 
BNP (mg/dL) 1300 
[834-
2078] 
1310 
[838.6-
2215] 
1237 [764-
2318.2] 
1220.9 
[920-2260] 
1153.5 
[765.8-
2241] 
0.894 
Abbreviations: ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; BNP: brain 
natriuretic peptide; CABG: coronary artery bypass graft; eGFR: estimated glomerular filtration rate; 
ICD: implantable cardiac defibrillator; LVEF: left ventricular ejection fraction; NYHA: New York heart 
association; NT-proBNP: n-terminal pro BNP; PCI: percutaneous coronary intervention 
  
Table 2: Clinical, rehospitalization, and mortality outcomes per quintile of 
baseline chloride 
 
Variable Q1 Q2 Q3 Q4 Q5 P for 
trend 
N = 431 430 346 452 301   
Clinical Outcomes       
Diuretic Response (kg/40 mg 
furosemide) 
-0.24 [-
0.52--
0.06] 
-0.31 [-
0.70--
0.10] 
-0.44 [-
0.83--
0.25] 
-0.50 [-
0.93--
0.25] 
-0.48 [-
0.94--
0.23] 
<0.00
1 
Weight change day 1 - 4 (kg) -2.5±3.2 -2.6±2.8 -2.9±3 -3.2±3 -2.9±2.7 0.009 
Total diuretic dose, day 1 - 3 (mg)  320 [180-
580] 
260.2 
[180-
429.5] 
220 [140-
360] 
200 
[120-
329.9] 
180 [120-
306.6] 
<0.00
1 
Total IV diuretic dose through day 7 (mg) 400 [160-
918] 
320 
[160-
615] 
241.6 
[120-
440] 
240 
[120-
460] 
210 
[113.2-
420] 
<0.00
1 
In-hospital thiazide diuretic use 24.6 
(106) 
19.8 (85) 15 (52) 15 (68) 15 (45) <0.00
1 
Inotropics (%(n)) 11.4 (49) 8.8 (38) 6.1 (21) 3.1 (14) 4.7 (14) <0.00
1 
Residual Congestion on day 7 (%(n)) 70.4 
(129) 
61.2 
(122) 
51.6 (79) 53.3 
(105) 
56.6 (90) 0.071 
Hemoconcentration on day 4 (%(n)) 50 (143) 58.5 
(165) 
58.3 
(144) 
62.2 
(199) 
69.3 
(147) 
<0.00
1 
WRF (≥0.3 mg/dL, and >25% increase in 
creatinine from baseline), day 7 
9.6 (40) 7.7 (32) 8.3 (28) 8.9 (39) 11.6 (34) 0.412 
WRF (≥0.3 mg/dL, and >25% increase in 
creatinine from baseline), day 14 
9.5 (39) 8.5 (35) 12.5 (42) 10.6 
(46) 
13.7 (40) 0.052 
Treatment failure due to Worsening 
Heart Failure (%(n)) 
15.1 (64) 10.3 (44) 9 (31) 6.5 (29) 6.6 (20) <0.00
1 
180-day mortality (%(n)) 25.5 
(110) 
20 (86) 15 (52) 11.9 
(54) 
13 (39) <0.00
1 
Abbreviations: IV: intravenous; WRF: worsening renal function 
  
Table 3: Cox regression analysis for baseline, day 7, and day 14 chloride 
 
 180-day mortality 
 Univariable Multivariable* 
 HR [CI] P-value HR [CI] P-value 
Chloride day 1 (per SD 
decrease) 
1.35 [1.22-1.49] <.001 1.08 [0.93-1.25] 0.310 
Sodium day 1 (per SD 
decrease) 
1.40 [1.28-1.55] <.001 1.14 [0.98-1.33] 0.079 
Chloride day 7 (per SD 
decrease) 
1.51 [1.36-1.68] <.001 1.25 [1.06-1.46] 0.007 
Sodium day 7 (per SD 
decrease) 
1.48 [1.33-1.65] <.001 1.08 [0.92-1.28] 0.341 
Chloride day 14 (per SD 
decrease) 
1.61 [1.44-1.80] <.001 1.32 [1.10-1.58] 0.003 
Sodium day 14 (per SD 
decrease) 
1.47 [1.32-1.63] <.001 0.94 [0.79-1.12] 0.476 
 
* Corrected for age, previous HF hospitalization, edema, SBP, log BUN, log creatinine, albumin, 
rolofylline treatment, and sodium or chloride 
 
Abbreviations: BUN: blood urea nitrogen; CI: confidence interval; HF: heart failure; HR: hazard 
ratio; SBP: systolic blood pressure; SD: standard deviation 
 
  
Table 4: Clinical characteristics per group with hypochloremia at baseline and/or 
day 14 
 
Variable HypoCl day 
1 & 14 
HypoCl day 1 HypoCl day 
14 
No HypoCl P for 
trend 
N = 122 98 177 1346   
Demographics      
Sex (% Male) 71.3 (87) 62.2 (61) 67.2 (119) 66.6 (896) 0.607 
Age (years) 66.1±11.7 69.4±13.5 71.2±11.5 70.1±11.4 <0.00
1 
LVEF (%) 28.1±14 34.2±16.6 30.8±13.1 32.4±12.4 0.085 
Systolic Blood Pressure 
(mmHg) 
112.7±17.2 120.6±18.4 119.5±17.5 126.4±16.9 <0.00
1 
Diastolic Blood Pressure 
(mmHg) 
68±11 71.7±13.4 70.9±11.2 75±11.6 <0.00
1 
Rolofylline administration 
(%) 
62.3 (76) 72.4 (71) 67.8 (120) 66.9 (900) 0.782 
Medical History      
Hypertension (%) 68 (83) 73.5 (72) 74.6 (132) 81.2 (1093) <0.00
1 
PCI (%) 25.6 (31) 20.6 (20) 33.7 (59) 25.2 (336) 0.854 
CABG (%) 36.9 (45) 19.4 (19) 24.6 (43) 19.6 (262) <0.00
1 
NYHA Class     <0.00
1 
I-II 18 (22) 19.4 (19) 19.2 (34) 16.3 (220)  
III 45.9 (56) 44.9 (44) 49.7 (88) 48.5 (653)  
IV 32 (39) 29.6 (29) 20.9 (37) 31 (417)  
ICD therapy (%) 34.4 (42) 13.3 (13) 24.3 (43) 13.5 (182) <0.00
1 
Laboratory Values      
Creatinine (mg/dL) 1.5 [1.2-1.9] 1.3 [1.1-1.7] 1.4 [1.2-1.8] 1.4 [1.1-1.8] 0.161 
eGFR (ml/min/1.73m2) 46.5 [36.2-
58.2] 
52.3 [38.4-
63.9] 
47.2 [34.9-
62.8] 
50.4 [37.5-
64.8] 
0.044 
Blood Urea Nitrogen (mg/dL) 39 [26-50.8] 28.5 [21-48.8] 30 [23-45] 28 [21-38] <0.00
1 
Sodium (mmol/L) 133 [130.2-
136] 
135 [132-138] 139 [137-
141] 
141 [138-
143] 
<0.00
1 
Potassium (mmol/L) 4.2 [3.8-4.6] 4.3 [3.9-4.6] 4.1 [3.8-4.5] 4.2 [3.9-4.7] 0.422 
Bicarbonate (mEq/L) 25 [22-29] 26 [23-29] 24 [21-27] 24 [21-26] <0.00
1 
Hemoglobin (g/dL) 12.7±2.1 13.2±2.2 12.5±1.8 12.7±1.9 0.163 
NT-proBNP (pg/mL) 3000 [3000-
5177] 
3000 [2971-
3000] 
3000 [3000-
4952] 
3000 [3000-
3622] 
0.003 
BNP (mg/dL) 1196.5 
[833-
1607.5] 
1507.5 
[1027.2-
2145.2] 
1430 
[907.5-
2390.8] 
1215.5 
[780.4-
2217.4] 
0.325 
Delta Sodium (day 14 – day 
1) -2 [-4-1] 2.5 [0-6] -5 [-7--2] 0 [-3-2] 
<0.00
1 
Delta Chloride (day 14 – day 
1) -1 [-3-1.8] 5.5 [4-9] -7 [-10--5] 0 [0302] 
<0.00
1 
Delta Potassium (day 14 – 0.3 [-0.1- 0.4 [-0.1-0.8] 0.3 [-0.2- 0.4 [0-0.8] 0.369 
day 1) 0.8] 0.8] 
Delta Bicarbonate (day 14 – 
day 1) -1 [-3-3] -2 [-4-1] 1 [-2-4] 0 [-2-3] 0.004 
Delta Creatinine (day 14 – 
day 1) 0 [-0.2-0.3] -0.1 [-0.2-0.1] 
0.2 [-0.1-
0.5] 0 [-0.2-0.2] 0.055 
Delta Blood Urea Nitrogen 
(day 14 – day 1) 2.5 [-5-10.8] -2[-9-5] 12 [2-25] 3 [-3-11] 
<0.00
1 
Delta eGFR (day 14 – day 1) 0 [-7.8-9.5] 2.4 [-2.4-10.2] 
-6.5 [-15-
1.8] 0 [-7.8-7.1] 0.003 
Clinical Outcomes      
Diuretic Response day 4 
(kg/40 mg furosemide) 
-0.20 [-0.39-
0.04] 
-0.31 [-0.67--
0.08] 
-0.20 [-0.44-
-0.05] 
-0.44 [-0.89--
0.20] 
<0.00
1 
Total diuretic dose, day 1 - 3 
(mg)  
412.5 [240-
800] 
260 [144.2-
541.9] 
310 [200-
560] 
215.1 [140-
360] 
<0.00
1 
In-hospital thiazide diuretic 
use 29.5 (36) 26.5 (26) 32.8 (58) 15.4 (207) 
<0.00
1 
Metolazone use 18 (22) 8.2 (8) 11.3 (20) 2.7 (37) 
<0.00
1 
180-day mortality (%) 30.3 (37) 13.3 (13) 25.4 (45) 11.2 (151) 
<0.00
1 
Abbreviations: BNP: brain natriuretic peptide; CABG: coronary artery bypass graft; eGFR: estimated 
glomerular filtration rate; ICD: implantable cardiac defibrillator; LVEF: left ventricular ejection 
fraction; NYHA: New York heart association; NT-proBNP: n-terminal pro BNP; PCI: percutaneous 
coronary intervention 
 
 
 
  
Supplementary figure 1: Chloride levels over time 
  
Supplementary table 1: Gain in C-index, and NRI in survival models 180-day 
mortality 
 
 C-index Gain in C-
index 
P-value NRI P-value 
Base model* 0.72     
   Add baseline chloride 0.72 0.0% 0.982 -0.05 0.627 
   Add day 7 chloride 0.73 1.6% <0.001 0.29 <0.001 
   Add day 14 chloride 0.73 1.8% <0.001 0.26 0.008 
* Base model includes age, previous HF hospitalization, edema, SBP, log BUN, log creatinine, 
albumin, rolofylline treatment, and sodium 
 
Abbreviations: BUN: blood urea nitrogen; HF: heart failure; SBP: systolic blood pressure 
 
 
  
Supplementary table 2: Cox regression analysis day 14 chloride (per SD decrease) 
per tertile of bicarbonate 
 
 180-day mortality 
 Univariable Multivariable* 
 HR [CI] P-value HR [CI] P-value 
Bicarbonate tertile 1 
21 [20-23] 
1.57 [1.32-1.87] <.001 1.36 [1.10-1.68] 0.004 
Bicarbonate tertile 2 
25 [24-26] 
1.69 [1.38-2.05] <.001 1.45 [1.13-1.85] 0.003 
Bicarbonate tertile 3 
28 [27-30] 
1.91 [1.52-2.39] <.001 1.48 [1.14-1.91] 0.003 
* Adjusted for age, previous HF hospitalization, edema, SBP, log BUN, log creatinine, albumin, 
rolofylline treatment, and sodium 
 
Abbreviations: BUN: blood urea nitrogen; CI: confidence interval; HF: heart failure; HR: hazard 
ratio; SBP: systolic blood pressure; SD: standard deviation 
 
  
Supplementary table 3: Cox regression analysis 180-day mortality delta chloride 
 
 180-day mortality 
 Multivariable* Multivariable* + day  7 or 14 chloride 
 HR [CI] P-value HR [CI] P-value 
Chloride day 7-1 
(per SD decrease) 
1.26 [1.12-1.41] <.001§ 1.16 [0.99-1.37] 0.072 
Chloride day 14-1 
(per SD decrease) 
1.31 [1.16-1.47] <.001§ 1.18 [0.98-1.41] 0.075 
* Corrected for age, previous HF hospitalization, edema, SBP, baseline sodium, log BUN, log 
creatinine, albumin and rolofylline treatment 
$ remains significant after addition of baseline chloride to the mv model 
 
Abbreviations: BUN: blood urea nitrogen; CI: confidence interval; HF: heart failure; HR: hazard 
ratio; SBP: systolic blood pressure; SD: standard deviation 
  
Supplementary table 4: multivariable linear regression model delta chloride day 
14 – day 1 
 
 
Variable Beta Coeff 95% CI T value p-value 
Sodium per SD -1.410 -1.64--1.18 -12.156 <0.001 
Bicarbonate per SD 0.887 0.65-1.19 7.742 <0.001 
Total cholesterol per SD 0.688 0.47-0.91 6.164 <0.001 
Orthopnea 1.272 0.14-2.40 2.072 0.028 
r2=0.107  
 
